Ratings ADDvise Group AB Nasdaq Stockholm

Equities

Market Closed - Nasdaq Stockholm Other stock markets 08:59:52 17/05/2024 pm IST			5-day change	1st Jan Change
7.3 ^SEK	0.00%		-2.41%	-46.48%

03/05	ADDvise Group AB Announces Board Appointments	CI
02/05	Addvise Group AB Announces Chief Executive Officer Changes	CI

From a short-term investment perspective, the company presents a deteriorated fundamental situation

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

	1st Jan change	Capi.	ESG Refinitiv
ADDVISE GROUP AB	-46.48%	14Cr	-
ABBOTT LABORATORIES	-5.43%	18TCr	C+
MEDTRONIC PLC	+4.30%	11TCr	C
BECTON, DICKINSON AND COMPANY	-3.09%	6.83TCr	A
DEXCOM, INC.	+5.86%	5.22TCr	B-
CENCORA, INC.	+8.15%	4.43TCr	B-
HOYA CORPORATION	+7.52%	4.27TCr	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	3.25TCr	B
TERUMO CORPORATION	+17.85%	2.6TCr	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	2.59TCr	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality